A 34% share-price jump is the market’s bluntest possible signal: investors believe the takeover of Option Care Health has materially advanced the company’s valuation story. $OPCH shares surged after McKesson and Clayton, Dubilier & Rice agreed to a $5.8 billion acquisition, turning speculation into a confirmed transaction with remarkable speed.

The deal was confirmed and finalized within 24 hours of the initial report surfacing. That pace matters. In merger-and-acquisition markets, the gap between rumor and confirmation can leave traders parsing uncertainty; here, that window narrowed almost immediately. The result was a sharp market reaction as investors processed the agreement involving Fortune 500 healthcare distributor McKesson and private-equity firm CD&R.

According to the reported transaction details, McKesson and CD&R agreed to a $5.8 billion takeover of Option Care Health. The development followed earlier reports, cited by the Financial Times, that the two parties were discussing a transaction of roughly $5 billion for the company. The progression from talks at approximately $5 billion to an agreed $5.8 billion takeover gives the episode a clear market narrative: initial speculation was quickly followed by a larger, formally confirmed deal.

A fast confirmation changes the trading conversation

For traders focused on immediate catalysts, the 34% move is the central fact. The jump reflects the market’s response to a defined corporate event rather than an earnings revision, product announcement, or broader healthcare-sector move. Once the agreement was confirmed, the focus shifted from whether a transaction might happen to what the deal means for the companies involved and for healthcare-services consolidation more broadly.

That distinction is important. The source material does not provide transaction terms beyond the $5.8 billion value, nor does it provide a premium, closing conditions, price targets, or other mechanics. Those omissions leave the confirmed headline value and the immediate share-price reaction as the cleanest data points available. Investors tracking the situation will therefore be watching the strategic implications rather than relying on unsupported assumptions about the transaction’s ultimate economics.

Why the buyer combination matters

The pairing of CD&R and $MCK brings two different forms of financial and operating reach to the acquisition. CD&R represents the private-equity-backed side of the transaction, while McKesson brings the profile of a Fortune 500 healthcare distributor. That combination places the takeover squarely within the continuing conversation around scale, specialization, and consolidation in US healthcare services.

Option Care Health’s relevance extends beyond the individual ticker. The company sits in an area watched by investors following home infusion and specialty pharmacy services, two segments specifically linked to the market’s interest in healthcare-service platforms. A transaction valued at $5.8 billion may prompt closer scrutiny of other US-listed healthcare companies operating in adjacent or related areas, particularly where strategic buyers and private-equity firms can pursue consolidation.

The broader M&A signal

The rapid sequence is as notable as the dollar value. Earlier reports identified discussions around a roughly $5 billion transaction; within 24 hours of the initial report, the deal was confirmed and finalized at $5.8 billion. That speed suggests that, at least in this case, the parties were prepared to move decisively once the discussions became public.

Still, one transaction does not establish a blanket valuation framework for the healthcare-services universe. The 34% reaction belongs to $OPCH and to this specific takeover announcement. Its broader significance is more measured: it provides a fresh, highly visible example of strategic and private-equity capital converging around a US healthcare-services company.